Although BRAF V600E variants were associated with recurrence and survival in the ICC cohort, non-V600E BRAF variants, which accounted for most of the BRAF variants in the whole cohort, demonstrated no association with prognosis. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.